Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Mayo Clinic
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer test
研究概览
简要总结
This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Self-identified Black individuals ≥ 45 years with an intact uterus
- •Assigned female sex at birth
- •Experience with abnormal uterine or post-menopausal bleeding (defined as vaginal bleeding between periods, heavy vaginal bleeding, vaginal bleeding after menopause, and/or red, brown, or pink colored vaginal discharge after menopause)
- •Willing to participate in a 45-minute virtual interview
排除标准
- •Previous or current diagnosis of endometrial cancer
研究组 & 干预措施
Observational
Participants complete a semi-structured interview on study.
干预措施: Non-Interventional Study (Other)
结局指标
主要结局
Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer test
时间窗: Baseline (30-minute virtual interview)
Information collected during a 30-minute virtual interview using mostly open-ended questions. The interviews will be transcribed and reviewed by the study team to identity themes and create coding categories. Coding categories will be used to organize the data into subthemes. Results will be reported in aggregate. Aggregate results will be disseminated to participants if they elect to receive them.
次要结局
未报告次要终点
研究者
Shariska Harrington
Principal Investigator
Mayo Clinic